Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable radiopharmaceutical company. This acquisition, worth $12.5 per share in cash, marks a significant step in Eli Lilly’s expansion in cancer treatment solutions. Advancing Cancer Treatments The acquisition brings together POINT’s […]